X-Linked Hypophosphatemia Market: Opportunities, Demand and Forecasts, 2018-2026

Posted by vakhas on January 24th, 2019

X-Linked Hypophosphatemia- Introduction

X-Linked hypophosphatemia (XLH) refers to an inherited disorder characterized by low phosphate concentration in the blood. The therapy for X-linked hypophosphatemia essentially involves phosphate supplements, corrective surgery, dental treatment, and growth hormone therapy. X-linked hypophosphatemia leads to weakening of bones, which can give rise to prolonged physical disabilities and subsequent pain. Patients detected with x-linked hypophosphatemia have bent legs, bone pain, short stature, and are prone to dental problems.

Recently, the Food and Drug Administration (FDA) approved the first drug for treatment of adults and children aged 1 year and above detected with x-linked hypophosphatemia. X-linked hypophosphatemia results in impaired growth & development of bones and creates issues with bone mineralization throughout a patient’s lifetime. 

Request For Sample @ https://www.factmr.com/connectus/sample?flag=S&rep_id=2667

X-Linked Hypophosphatemia Market Dynamics

The x-linked hypophosphatemia market continues to be driven by multipronged factors, ranging from growing prevalence of genetic diseases to rising expenditure on healthcare services. Moreover, proactive initiatives   on research and development activities are also expected to influence the x-linked hypophosphatemia market landscape. For instance, Yale Center for X-Linked Hypophosphatemia has been making continuous research and development efforts to ensure the well-being of patients suffering from XLH.

The time-intensive introduction and approval of effective drugs for x-linked hypophosphatemia continues to be a pervasive trend influencing the growth of this market. Limited availability of treatment options and low awareness levels about x-linked hypophosphatemia, especially across developing countries, might pose challenges for the market growth over the assessment period. Manufacturers in the x-linked hypophosphatemia market are introducing viable antibodies to arrest the loss of phosphate levels.